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The high cure rate of children with acute
lymphoblastic leukemia (ALL) represents
one of the most remarkable success sto-
ries in the war on cancer. Stepwise
improvements in therapy that have taken
place over the last four decades have
increased survival rates from 15% to the
75%–80% observed today (Pui et al.,
2004). Many factors have led to this high
cure rate, including: (1) the use of combi-
nation chemotherapy, (2) presympto-
matic treatment of the central nervous
system, a sanctuary site, and, more
recently, (3) the use of intensified thera-
peutic regimens. These major advances
have been derived empirically through
carefully controlled, randomized multi-
institutional clinical trials. More recently,
clues to the underlying pathogenesis of
ALL have come from the identification of
somatically acquired genetic lesions in
leukemic blasts, such as specific chro-
mosomal translocations and gain or loss
of whole chromosomes. It is quite
remarkable that relatively little improve-
ment can be attributed to this new infor-
mation. If empiric therapy can lead to the
75%–80% cure rates seen today, what
impact can we expect from more recent
breakthroughs in laboratory science?
While the extremely high cure rates
for these children are gratifying, major
hurdles still exist. The therapy delivered
today can be associated with significant
short- and long-term side effects.
Moreover, close to one in four children will
suffer a recurrence, and their outcome is
dismal. Identifying the biological mecha-
nisms that mediate tumor response and
resistance will undoubtedly lead to more
effective and tumor-specific therapy.
A number of fundamental questions
about cellular drug resistance have occu-
pied investigators for years. Do drug-
resistant tumor cells exist at diagnosis, or
are they acquired during therapy? If pre-
sent at diagnosis, are resistance mecha-
nisms shared by the total population of
tumor cells, or does the problem lie in a
much smaller subset of blasts that may
prove difficult to identify and study at initial
diagnosis? Finally, will resistance mecha-
nisms prove to be unique to individual
agents or classes of drugs, or will domi-
nant pathways that confer resistance to
many agents emerge? The article by
Lugthart and colleagues in this issue of
Cancer Cell addresses these important
questions (Lugthart et al., 2005).
The generation of resistant cell lines
in vitro rarely mimics the de novo drug
resistance seen in patients. However,
these investigators have shown previ-
ously that the relative in vitro drug sensi-
tivity of individual ALL patient samples
correlates with outcome, suggesting that
drug resistance exists at diagnosis and
that there are certain features shared by
the entire population that are associated
with the eventual outgrowth of a truly
resistant clone (Den Boer et al., 2003).
In a recent study (Holleman et al.,
2004), the authors identified gene expres-
sion signatures that were associated with
unique sensitivity to four commonly used
drugs. There was little overlap between
these signatures, indicating that diverse
pathways mediate tumor response. This
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Childhood acute lymphoblastic leukemia is one of the most curable of all human cancers, but new approaches are urgent-
ly needed for children who relapse and to avoid severe side effects of curative therapy. Work from the laboratories of Rob
Pieters and William Evans, including a paper in this issue of Cancer Cell, has led to the identification of genes whose
expression correlates with drug crossresistance and long term outcome.The goal is now to integrate these and other find-
ings using gene expression technology into the care of children with the most common pediatric malignancy.
Figure 1. Risk group stratification in pediatric
ALL
A combination of clinical and biological fea-
tures of the tumor and host are currently
used for risk group stratification. These fea-
tures include a patients age and initial white
blood cell count (WBC), genetic features of
leukemic blasts, and early treatment
response. Therapy is based on the predicted
risk of relapse, such that children in lower risk
groups receive less intensive treatment than
those in higher risk groups. The event-free sur-
vival (EFS) rates for patients in different risk
groups are shown.
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result is a bit sobering, since it might
prove daunting to modulate many path-
ways in an attempt to improve the sensi-
tivity of leukemia cells to conventional
agents. In the current paper (Lugthart et
al., 2005), the authors turn their attention
to discovering pathways that are respon-
sible for governing response to multiple
drugs (the same four used in the earlier
study). One might have expected that
more distal effector pathways down-
stream of the genotoxic or cytotoxic “hit”
supplied by the drugs might be identified
in such an analysis. They identified two
major patterns of in vitro response—one
associated with poor response to all four
agents, and the other, a more curious
one, characterized by a discordant rela-
tionship between sensitivity to vincristine
(VCR) and L-asparaginase (ASP).
The authors searched for robust
gene expression signatures that defined
the most resistant and sensitive samples
(e.g., top and bottom quartiles) and
again found a seemingly diverse group
of genes whose expression appeared to
correlate with sensitivity or resistance to
multiple anticancer agents. As in their
earlier study, few of these genes have
been previously linked to drug resis-
tance. The crossresistance profile was
associated with older age, a well-known
adverse prognostic variable. Samples
characterized by either the presence of
the t(12;21) (TEL-AML1) or hyper-
diploidy were more likely to be cross-
sensitive and have a favorable VCR-ASP
discordant phenotype. There was little
overlap between the sensitivity/resis-
tance signatures described in this report
and gene expression signatures discov-
ered previously that predict genetic sub-
groups such as TEL-AML1 expression or
hyperdiploidy (Yeoh et al., 2002; Moos et
al., 2002). These results indicate again
that the signatures are associated with
intrinsic drug resistance/sensitivity path-
ways and are not simply surrogate mark-
ers for these genotypes.
The crossresistance gene signature
did predict outcome in an independent set
of patients, emphasizing the predictive
value of this score. In contrast, the ASP-
VCR gene expression score was predic-
tive in the COALL/DCOG (German
Cooperative Study Group for Childhood
Acute Lymphoblastic Leukemia/ Dutch
Childhood Oncology Group), trials but not
in patients treated on St. Jude protocols.
This result underscores an important
point that should not be overlooked—all
predictive variables are highly dependent
on the type of therapy delivered. So it is
not surprising that some gene expression
signatures associated with outcome
might not be confirmed in trials using dif-
ferent treatment approaches.
This article, as well as prior results
from the same group of investigators,
begins to shed light on the biological
basis of treatment failure. How, then,
might these important results be applied
to treatment today? First, the identifica-
tion of pathways associated with drug
resistance might define new targets for
potential modulation. This is crucial if fur-
ther improvements in therapy are to be
gained, as the maximal benefit from dose
intensification has already been reached
in most circumstances. Blocking drug
resistance pathways might be expected
to improve outcome and could lead to the
ability to decrease the dose of, or elimi-
nate entirely, toxic chemotherapeutic
agents. However, this will be challenging
given the diversity of resistance genes
identified in this report that do not easily
point to attractive targets being pursued
by industry currently. Moreover, the com-
plexity of the response relationships,
such as discordant patterns of respon-
siveness to vincristine and asparaginase,
might prove problematic.
The second potential application of
these results is their use in risk classifi-
cation. Treatment is optimally tailored to
each individual patient’s risk of failure so
that chances for cure can be maximized,
while unnecessary toxicity can be avoid-
ed. A variety of clinical (age, gender) and
laboratory (white blood cell count, blast
surface immune phenotype, blast geno-
type) characteristics are now used to
stratify patients into different risk groups
(Figure 1) (Smith et al., 1996). Those
predicted to have a good outcome typi-
cally receive less aggressive therapy,
while those with a predicted higher risk
of treatment failure receive more intensi-
fied therapy. In spite of these tools, how-
ever, many patients who fail treatment
are those who were predicted to have a
good outcome initially.
Can the gene expression signatures
discovered by Lugthart et al. be used to
augment current risk classification
schemes? A few observations require
consideration in this regard. First, the four
drugs used to assess sensitivity in this
report are used commonly during the first
month of ALL therapy, a phase called
induction. The overwhelming majority
(>98%) of patients with ALL, regardless
of associated prognostic features, enter
remission at the end of induction, where
there is no visible appearance of blasts in
the bone marrow or blood. In addition,
close to 50% of patients with adverse
gene signatures as defined by Lugthart et
al. are still cured of their disease, so alter-
ing therapy based on the crossresistance
or VCR-ASP score alone seems unwar-
ranted. However, these signatures might
be used in conjunction with current risk
criteria. One of the most important mea-
sures of drug sensitivity is the in vivo sen-
sitivity defined by the kinetics of blast
regression in the peripheral blood and/or
bone marrow. Children whose blasts dis-
appear by day 7 of treatment have a
much better outcome compared to those
with a slower rate of regression (Gaynon
et al., 1997). Newer techniques designed
to detect blasts well below the previous
threshold defined by light microscopy,
such as flow cytometry and molecular
techniques focused on clonal markers
(antigen receptor or translocations), now
make it possible to detect one leukemic
blast in a background of 104 or 105 normal
cells (Szczepanski et al., 2001).
Importantly, patients showing a slow
early response can have their therapy
augmented, and this has been shown to
improve outcome (Nachman et al., 1998).
The in vivo sensitivity of the samples
was not factored into the analysis by the
authors, and it will be interesting to
determine whether profiles that predict
crossresistance also predict slow early
response to therapy as measured by
marrow blast clearance and the pres-
ence of minimal residual disease. Cario
et al. (2005) used gene arrays to define a
signature associated with residual dis-
ease at day 29 in a different cohort of
patients, and there appears to be no
overlap with the gene sets found by
Lugthart et al. Nonetheless, one
approach might be to use both the in
vitro gene expression profiles and the
kinetics of regression in vivo to risk-clas-
sify patients. Perhaps the 50% of
patients with adverse crossresistance
scores who are cured are those display-
ing rapid disease regression in vivo.
Over the past forty years, building
successful therapy for children with ALL
has relied on the empiric application of
drugs whose exact biological effects
were uncertain to say the least.
Undoubtedly, physicians, patients, and
family members will some day look back
on this era as relatively primitive com-
pared to what will unfold shortly in the
age of molecular genetics. However, to
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label the therapy as primitive would not
do justice to the resounding success in
the number of lives saved and the dedi-
cated professionals who pioneered
cures for these children.The fact is that if
the 75% cure rate seen today was estab-
lished with only modest insight into the
underlying biology of ALL, then we
should expect nothing short of 100%
cure as well as successful preventive
strategies in the decades to come.
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Myeloproliferative disorders (MPDs) are
clonal malignancies characterized 
by overproduction of one or more
hematopoietic lineages with relatively
normal differentiation (Van Etten and
Shannon, 2004). The World Health
Organization (WHO) classifies chronic
myeloid leukemia (CML), polycythemia
vera (PV), essential thrombocythemia
(ET), chronic idiopathic myelofibrosis
(CIMF), and the related disorders chron-
ic eosinophilic leukemia (CEL) and idio-
pathic hypereosinophilic syndrome
(HES) as distinct MPDs. Atypical CML,
chronic myelomonocytic leukemia
(CMML), and juvenile myelomonocytic
leukemia (JMML) comprise a related
group of “overlap” disorders in which
myeloproliferation is prominent, but the
bone marrow also shows aberrant matu-
ration (myelodysplasia). Laboratory and
clinical observations such as de novo
chromosomal translocations (e.g.,
t[9;22] in CML and t[5;12] in some cases
of CMML), an increased risk of JMML in
children with neurofibromatosis and
Noonan syndrome, and the unexpected
responses of some patients with HES to
imatinab mesylate provided clues that
facilitated identifying molecular lesions
that play a central role in the pathogene-
sis of MPDs and “overlap” diseases
(Figure 1). Aberrant activation of kinase
signaling cascades and hyperactive Ras
have emerged as common biochemical
themes in these disorders, and studies in
animal models strongly imply that many
of the mutations found in human patients
can initiate MPD-like diseases in vivo
(Van Etten and Shannon, 2004).
A paper by Levine et al. (2005) in this
issue of Cancer Cell, and data published
in the Lancet and Nature (Baxter et al.,
2005; James et al., 2005), report JAK2
point mutations in most patients with PV
and in a substantial proportion of ET and
CIMF. These results are satisfying, as
they follow logically from the known role
of the JAK2 kinase in hematopoietic pro-
liferation and are consistent with previous
studies of PV patient samples. The four
mammalian Janus (JAK) kinases are
recruited by ligand binding to cytokine
receptors, where they are activated by
trans-phosphorylation and, in turn, phos-
phorylate critical tyrosine residues on the
receptor that can then serve as docking
sites for members of the STAT (signal
transducer and activation of transcription)
family and for other signaling molecules
(O’Shea et al., 2002). Specific cytokine
receptors recruit and activate distinct
pairs of JAK and STAT proteins. JAK2 is
the primary tyrosine kinase activated by
erythropoietin (EPO), and is essential for
definitive erythropoiesis (Parganas et al.,
1998). Many of the effects of JAK2 are
mediated through the recruitment of
STAT5 to phospotyrosyl residues on the
EPO, interleukin 3 (IL-3), and granulo-
cyte-macrophage colony stimulating fac-
tor (GM-CSF) receptors. Interestingly,
JAKing up hematopoietic proliferation
Mutations that deregulate proliferation and survival pathways have emerged as a common molecular theme in the patho-
genesis of myeloproliferative disorders (MPDs).Three studies now report an amino acid substitution in the JAK2 kinase in
most patients with polycythemia vera as well as in some cases of essential thrombocythemia and chronic idiopathic
myelofibrosis. Functional analysis demonstrates that this mutation confers erythropoietin-independent growth in vitro,
deregulates signaling pathways downstream of JAK2, and causes polycythemia in mice.These results open new avenues
for diagnosing and classifying patients with these disorders, and identify a new molecular target for drug discovery.
